Comparative Pharmacology
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 128.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXABRIX versus ISOVUE 128.
HEXABRIX vs ISOVUE-128
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Isovue-128 (iopamidol) is a nonionic, water-soluble, radiographic contrast medium that enhances imaging by attenuating X-rays, thereby increasing contrast between vascular structures and surrounding tissues. Its mechanism is based on the high iodine content which absorbs X-rays, allowing visualization of blood vessels and organs during angiography, urography, and CT scans.
Intravenous: 0.3-0.6 mL/kg (maximum 100 mL) for urography; 40-80 mL for CT enhancement.
Adult: 50-200 mL (0.5-2.0 mL/kg) intravenously, single dose for contrast-enhanced CT; for angiography, dose and rate vary by procedure.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours with GFR <30 mL/min).
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
Renal: >95% excreted unchanged in urine via glomerular filtration; fecal/biliary: <5%.
Category C
Category C
Contrast Media
Contrast Media